Seraxis
Business Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
20271 Goldenrod Ln Ste 2085, Germantown,...Phone Number
(240) 429-1053Website
www.seraxis.comRevenue
$6.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Seraxis
SERAXIS, found in 2013, is a privately held biotechnology company with operations located in Germantown, Maryland. SERAXIS has a proprietary cell line and technology to manufacture transplant-ready pancreatic islets for treatment of insulin-dependent diabetes. SERAXIS also developed SeraGraft, a device that safely protects these human pancreas cells from the immune system.Explore more
Seraxis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Seraxis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Seraxis has new funding data
Earning: See what the market has to say on Seraxis recently announced quarterly report
Check if Seraxis has recently received funding, and reach out quickly before it becomes old news!
Check out if Seraxis is spiking on competitors!
Seraxis, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Seraxis launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Seraxis
Click to see if Seraxis had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Seraxis as Masked Content
Find more new buyers
Compare Similar Companies to Seraxis
Compare insights from companies similar to Seraxis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Seraxis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Seraxis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Seraxis.
Seraxis financials insights
Gather financial insights about Seraxis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$87K
Series C
$40M
Seraxis Tech Stack
A closer look at the technologies used by Seraxis
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
New Hire
Executive Move
Funding
Funding
Seraxis News & Media
Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA
Manuscript describes the unique character of a pancreatic endocrine cell population derived from a non-pluripotent stem cell that closely resembles native islets in composition and in vivo function. Dr. William Rust, CEO of Seraxis, will deliver a lecture at the IPITA-IXA-CTRMS Joint Congress on October 29 at 10:00 a.m. in San Diego entitled “Novel stem cell-derived islet-like clusters potently control rodent blood glycemia”. Seraxis will be taking meetings at BIO-Europe, November 6-8, in MunichSeraxis to Provide Oral Update on Its Pancreatic Organoid Candidate for Functional Cure of T1D at the 59th Annual Meeting of the EASD
Dr. William Rust will give an oral presentation on Seraxis’ proprietary technology for the production of therapeutic pancreatic organoids from pancreas-derived stem cells, as well as review initial diabetes model data of functional cure of Type 1 Diabetes. Seraxis’ presentation, entitled “Stem-cell Derived Islets for Treating Diabetes”, will be delivered in the session entitled "Transplantation of Islet and Stem Cells Today and Tomorrow".Seraxis Announces Closing of Second VC Tranche and Successful Completion of Preclinical Studies of Pancreatic Organoids From Seraxis’ Novel Pancreas-Derived Stem Cells
Leadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran Total venture funding tops $50M to dateLate-Breaking Results of a Preclinical Efficacy Study Presented at ENDO 2023 Show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia
Seraxis today announced late-breaking results of an ongoing study evaluating the efficacy of SRE pancreatic clusters in a type 1 diabetes model a ...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Seraxis
Sign Up For FreeTo access detailed company insights
SERAXIS, found in 2013, is a privately held biotechnology company with operations located in Germantown, Maryland. SERAXIS has a proprietary cell line and technology to manufacture transplant-ready pancreatic islets for treatment of insulin-dependent diabetes. SERAXIS also developed SeraGraft, a device that safely protects these human pancreas cell... Read More
